HOSPITAL UNIVERSITARIO RUBER
Departamento
IRB Barcelona - Institute for Research in Biomedicine
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de IRB Barcelona - Institute for Research in Biomedicine (7)
2024
-
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
ESMO Open, Vol. 9, Núm. 9
-
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
The Lancet Oncology, Vol. 25, Núm. 9, pp. 1231-1244
2020
-
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Nature Communications, Vol. 11, Núm. 1
2018
-
MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer
Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221
-
Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)
Nature Cell Biology
2017
-
Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer
Cancer Research, Vol. 77, Núm. 9, pp. 2213-2221
-
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
Oncogene, Vol. 36, Núm. 19, pp. 2737-2749